Retatrutide Side Effects: What the Clinical Research Actually Shows (2026)

Human Clinical Trial Data

Retatrutide is one of the most closely watched metabolic research compounds of the decade. Because it is still investigational, the most common question researchers ask is a simple one: what side effects has retatrutide actually caused in published clinical trials? This guide answers that using only peer-reviewed Phase 1 and Phase 2 data — no hype, no exaggeration, and clear about what the research does and doesn’t yet tell us.

In this article

What is retatrutide?

Retatrutide (development code LY3437943) is an investigational triple agonist — a single molecule that activates three receptors at once: the GLP-1, GIP, and glucagon receptors. That third target, the glucagon receptor, is what separates it from dual agonists like tirzepatide and is thought to add an energy-expenditure (thermogenic) component on top of appetite suppression and improved insulin response.

In published trials it has produced among the largest weight reductions reported for any metabolic agent to date. But larger pharmacological effects also come with a side-effect profile that researchers need to understand. Importantly, retatrutide is not approved by Health Canada, the FDA, or any regulatory body; everything below comes from controlled clinical studies, not from approved-product labeling.

The most common retatrutide side effects

Across the Phase 2 obesity trial published in The New England Journal of Medicine (Jastreboff et al., 2023), the side effects reported were overwhelmingly gastrointestinal and were mostly described as mild to moderate. The pattern closely mirrors what is seen with other incretin-based compounds (semaglutide, tirzepatide), which makes biological sense given the shared GLP-1 mechanism.

Source: Jastreboff et al., NEJM 2023 In the Phase 2 trial, the most frequently reported adverse events were nausea, diarrhea, vomiting, and constipation. These gastrointestinal effects were generally dose-related — more common at higher doses and during dose escalation — and most were graded mild to moderate in severity.
Reported effect Category General pattern in trials
Nausea Gastrointestinal Most common; dose-related
Diarrhea Gastrointestinal Common; dose-related
Vomiting Gastrointestinal Common, esp. at higher doses
Constipation Gastrointestinal Common
Decreased appetite Metabolic / expected Expected pharmacology, not always “adverse”
Increased heart rate Cardiovascular Observed; discussed below

Gastrointestinal effects: the dominant theme

If there is one headline finding about retatrutide’s tolerability, it is that the side effects are mostly digestive. This is characteristic of the entire GLP-1 receptor agonist class: slowing gastric emptying and acting on appetite-regulating pathways naturally produces nausea and altered bowel habits in a meaningful share of subjects.

The clinically important nuance is timing. In the published data, these effects clustered around the periods when the dose was being increased. Once a given dose was maintained, tolerability tended to improve. This is why trial protocols use gradual dose escalation rather than starting at the top dose — a design choice specifically intended to reduce the gastrointestinal burden.

Heart rate and cardiovascular signals

Beyond the digestive effects, the trials noted a small increase in heart rate, which is again consistent with the incretin drug class. Researchers track this closely because it is a recognized class-wide observation rather than something unique to retatrutide.

Why this matters in research Heart-rate changes are a standard monitoring parameter in incretin trials. Their presence in retatrutide studies is expected given the GLP-1 component, and it is one reason cardiovascular endpoints are a focus of ongoing later-phase research.

Why dose escalation is central to the side-effect story

You cannot accurately discuss retatrutide’s side effects without discussing dose. The published trials tested a range of dose levels, and a consistent finding was that higher doses produced both greater effects and more frequent gastrointestinal adverse events. The gradual titration approach used in the studies was the main tool for managing this trade-off.

This dose-dependence is the single most important concept for anyone studying the compound: the side-effect profile is not a fixed property of the molecule — it scales with exposure and changes during escalation.

The honest limits of the current data

Here is the part most pages selling these compounds leave out. The retatrutide safety picture, while encouraging in early trials, is still incomplete:

  • It is investigational. Long-term safety over years of use has not been established the way it has for older, approved agents.
  • Phase 2 is not the final word. Larger and longer Phase 3 trials are needed to characterize rarer adverse events and durability of the safety profile.
  • Trial conditions are controlled. Adverse-event rates from supervised clinical trials with defined dosing and monitoring do not automatically translate to other settings.
  • No regulatory approval. Retatrutide has not been reviewed or approved for therapeutic use by Health Canada or the FDA at the time of writing.

An accurate summary is therefore: in published Phase 1 and Phase 2 research, retatrutide’s side effects were predominantly mild-to-moderate gastrointestinal events that were dose-related and most prominent during escalation, alongside a modest heart-rate increase — with long-term and large-scale safety data still pending.

Research-grade retatrutide, lab-verified

Every batch third-party tested at ≥99% purity with a published Certificate of Analysis. For laboratory research use only.

View Retatrutide →

Frequently asked questions

What is the most common retatrutide side effect?

In published clinical trials, nausea was the most frequently reported side effect, followed by other gastrointestinal effects such as diarrhea, vomiting, and constipation. These were generally dose-related and most often mild to moderate.

Are retatrutide’s side effects different from semaglutide or tirzepatide?

The type of side effects is broadly similar across this drug class — mostly gastrointestinal — because all three share the GLP-1 mechanism. For a deeper comparison of the three compounds, see our Semaglutide vs Tirzepatide vs Retatrutide research comparison.

Why do the side effects happen mostly during dose increases?

Tolerance to the gastrointestinal effects tends to build over time at a stable dose. Trials therefore escalate the dose gradually, which reduces how often and how severely these effects occur.

Is retatrutide approved or safe for human use?

No. Retatrutide is an investigational compound that has not been approved by Health Canada, the FDA, or any regulatory authority. It is sold strictly for laboratory and research purposes and is not for human or animal consumption.

References

  1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514–526. PMID: 37366315.
  2. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234–1247. PMID: 35953067.
  3. Rosenstock J, Frias J, et al. Retatrutide research in type 2 diabetes: Phase 2 findings. The Lancet. 2023. (Verify exact citation on PubMed before publishing.)
Disclaimer. This article is for educational and research-reference purposes only. It summarizes published scientific literature and is not medical advice. Retatrutide is sold exclusively for in-vitro laboratory research and is not approved for human or animal use by Health Canada, the FDA, or any regulatory authority. Nothing here should be interpreted as encouraging or instructing human use. Always consult the primary published sources and a qualified professional.
Back to blog